Drug-induced hypo- and hyperprolactinemia: mechanisms, clinical and therapeutic consequences (Q38100267)

28 August 2017

title

Drug-induced hypo- and hyperprolactinemia: mechanisms, clinical and therapeutic consequences (English)

1 reference

28 August 2017

Victor Voicu

1 reference

28 August 2017

Andrei Medvedovici

series ordinal

1 reference

28 August 2017

Aurelian Emil Ranetti

series ordinal

1 reference

28 August 2017

Flavian Ştefan Rădulescu

series ordinal

1 reference

28 August 2017

language of work or name

English

0 references

publication date

21 April 2013

1 reference

Expert Opinion on Drug Metabolism & Toxicology

28 August 2017

published in

1 reference

28 August 2017

1 reference

28 August 2017

1 reference

28 August 2017

page(s)

955-968

1 reference

Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists.

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Prolactin: the new biology of an old hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

New concepts in prolactin biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Biochemical and functional aspects on the control of prolactin release by the hypothalamo-pituitary GABAergic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Immunocytochemical and pharmacological evidence for an intrinsic cholinomimetic system modulating prolactin and growth hormone release in rat pituitary

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Estrogen receptor-alpha mediates the epidermal growth factor-stimulated prolactin expression and release in lactotrophs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Molecular mechanisms of prolactin and its receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Structural features of prolactins and growth hormones that can be related to their biological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Prolactin acts as a potent survival factor for human breast cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

The role of prolactin in mammary carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Curatively resected primary malignant melanoma of the esophagus: report of a case

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Schizophrenia and breast cancer incidence: a systematic review of clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

The risk for breast cancer is not evidently increased in women with hyperprolactinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Gender differences in the prescribing of antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

The effects of hyperprolactinemia on bone and fat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

HPA- and HPT-axis alterations in chronic posttraumatic stress disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Prolactin, psychological stress and environment in humans: adaptation and maladaptation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Increased pituitary volume in antipsychotic-free and antipsychotic-treated patients of the AEsop first-onset psychosis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

From galactorrhea to osteopenia: rethinking serotonin-prolactin interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Hyperprolactinaemia as an adverse effect in regulatory and clinical toxicology: role in breast and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

New insights on the consequences of biotransformation processes on the distribution and pharmacodynamic profiles of some neuropsychotropic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

An agonist-antagonist interaction model for prolactin release following risperidone and paliperidone treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Adverse effects of atypical antipsychotics : differential risk and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Effects of short- and long-term risperidone treatment on prolactin levels in children with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Prolactin and dopamine: what is the connection? A review article

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Property-based design: optimization of drug absorption and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Lipophilicity in PK design: methyl, ethyl, futile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

QSAR modeling of the blood-brain barrier permeability for diverse organic compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Domperidone: review of pharmacology and clinical applications in gastroenterology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Brain drug development and brain drug targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

An update of fast-off dopamine D2 atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Relationship between prolactin secretion, and plasma risperidone and 9-hydroxyrisperidone concentrations in adolescents with schizophreniform disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

In vitro P-glycoprotein efflux inhibition by atypical antipsychotics is in vivo nicely reflected by pharmacodynamic but less by pharmacokinetic changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Tardive dyskinesia in schizophrenia is associated with prolactin-related sexual disturbances

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Coherent view of non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Toxicological considerations of acetylcholinesterase reactivators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Reversal of symptomatic hyperprolactinemia by aripiprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Change in sexual dysfunction with aripiprazole: a switching or add-on study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Evidence for the partial dopamine-receptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorogenic hyperprolactinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Aripiprazole possibly worsens psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Aripiprazole-induced behavioural disturbance related to impulse control in a clinical setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Neuroleptic-induced supersensitivity psychosis in patients with bipolar affective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Partial agonists in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Medication-induced hyperprolactinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Osteoporosis and fracture risk in people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Estrous cycle-dependent histology and review of sex steroid receptor expression in dog reproductive tissues and mammary gland and associated hormone levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

Sexual Dysfunction in First-Episode Schizophrenia Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.791283

10.1517/17425255.2013.791283

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference